Results 121 to 130 of about 1,772,527 (156)
KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations
European Journal of Haematology, Volume 117, Issue 5, Page 1318-1326, November 2026.ABSTRACT
Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert +6 morewiley +1 more sourceDose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia
European Journal of Haematology, Volume 117, Issue 5, Page 1358-1368, November 2026.ABSTRACT
Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer +12 morewiley +1 more sourceSustained disease remission with reduced‐intensity allogeneic hematopoietic cell transplant for VEXAS syndrome
HemaSphere, Volume 10, Issue 11, November 2026.Bhavisha A. Patel, Ajoy Dias, Daniele Avila, Tonya Jenkins, Lisa Duncan, Roxanne Merkel, Alice Fike, Julie Onyechi, Xingmin Feng, Fernanda Gutierrez‐Rodrigues, Ivana Darden, Shanni Liu, Benjamin Turturice, Jennifer Hendricks, Erin Flannelly, Kristen Cole, Kanak Parmar, Ruba Shalhoub, Colin O. Wu, Jennifer Lotter, Boeui Kang, Sachiko Kajigaya, Corina Gonzalez, Chuanfeng Wu, Marcela A. Ferrada, Jennifer Cuellar‐Rodriguez, Mary Czech, Katherine R. Calvo, Richard W. Childs, David B. Beck, Neal S. Young, Sung‐Yun Pai, Dennis D. Hickstein, Peter C. Grayson, Emma M. Groarke +34 morewiley +1 more sourceIncreased Expression of CD70 in Relapsed Acute Myeloid Leukemia After Hypomethylating Agents
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse.Panowski, Siler, Lu, Wei, Borthakur, Gautam, Wang, Wei, Arandhya, Akanksha, Norwood, Kevin, McAllen, Salome, Vega, Francisco, Szenes, Victoria, Gomez, Javier A, Solis, Luisa M, Khan, Khaja, Burks, Jared K, Wang, Wei-Lien, Rezvani, Katayoun, Duenas, Daniela, Balakumaran, Arun, Basar, Rafet, Marin, David, Kumar, Bijender, Wang, Sa, Srinivasan, Surabhi, Acharyal, Sunil, Prashad, Sacha, Daher, May, Marques-Piubelli, Mario L +25 morecore +1 more sourceThe role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high‐risk myelodysplastic syndromes
British Journal of Haematology, Volume 209, Issue 5, Page 2335-2340, November 2026.George Vrachiolias, Eleftheria Lamprianidou, Athanasios Tasis, Theodoros Spyropoulos, Despoina Dimitriou, Chryssa Kymparidou, Christina Misidou, Konstantinos Liapis, Emmanouil Spanoudakis, Maria Koffa, Menelaos Papoutselis, Iliana Stamatiou, Elsa Bernard, Elli Papaemmanuil, Ioannis Mitroulis, Ioannis Kotsianidis +15 morewiley +1 more source